About Tessera Therapeutics
Tessera Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2017 by Robert Citorik. New genome engineering technology is provided for treating multiple diseases. Tessera Therapeutics has raised $610 million across 3 funding rounds from investors including T. Rowe Price, Flagship Pioneering and Temasek. The company has 149 employees. Its chief executive, as recorded, is Michael Severino. Its website tesseratherapeutics.com draws about 11 thousand monthly visits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Genomics. Its legal entity is TESSERA THERAPEUTICS, INC. Its competitors include Beam Therapeutics, eGenesis and Korro Bio; 3 of its 3 listed competitors have raised funding.
Company details
Tessera Therapeutics was founded in 2017 in Cambridge, United States, within the biotechnology sector. Genome engineering solutions are developed to address diseases at their genetic source. RNA-based gene writing is utilized to modify base pairs, perform small insertions or deletions, and integrate full genes into the genome. Operations center on advancing therapeutic applications for various conditions.
- Headquarters Cambridge, United States
- Employees 149
- Founders Robert Citorik
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website tesseratherapeutics.com
- Social LinkedIn X
- Legal Name Tessera Therapeutics, Inc
- Total Equity Funding$610M (USD)
in 3 rounds
- Latest Funding Round$300M (USD), Series C
Apr 2022
- InvestorsT. Rowe Price
& 16 more
- Employee Count149
Funding Insights of Tessera Therapeutics
Tessera Therapeutics has successfully raised a total of $610M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $300 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $610M
- Total Rounds 3
- Last Round Series C — $300M
- First Round $80M
(Dec 2017)
- Investors Count 17
All 3 funding rounds of Tessera Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $300M | Series C | – | ADIA, Artis Ventures | |
| Jan 2021 | $230M | Series B | – | Altitude Life Science Ventures, Alaska Permanent Fund | |
| Dec 2017 | $80M | Series B | – | Temasek |
17 investors in total: 17 institutional.
Investors in Tessera Therapeutics
Tessera Therapeutics has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include T. Rowe Price, Flagship Pioneering and Temasek.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage life sciences sectors focused VC firm investing in the US | altitudelsv.com | Kirkland, United States | ||
Early-stage startups are invested in by Artis Ventures. | av.co | San Francisco, United States | ||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Support is provided for longevity breakthrough initiatives by Longevity Vision Holding. | lvf.vc | New York, USA | ||
Healthcare startups are funded by this venture capital firm. | Ponte Vedra, United States | |||
Venture capital firm investing in multiple sectors | marchcp.com | Santa Monica, United States | ||
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
Government-backed investments are directed toward healthcare, fintech, and various sectors. | edbi.com | Singapore, Singapore | ||
Diversified investment management firm | karstpeak.com | Hong Kong, China |
Investor details for Tessera Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tessera Therapeutics
88 people are tracked at Tessera Therapeutics (39 in leadership, 12 in board & advisors, 37 in team); the tracked headcount is 149.
| Name | Role | Group |
|---|---|---|
Robert Citorik | Co-Founder & Director | Leadership |
Michael Severino | CEO | Leadership |
David Davidson | Chief Medical & Development Officer | Leadership |
Miles C. Duncan | Associate Director - Genotox Off-target Discovery And Validation | Leadership |
Stephen Garbacz | Head, Finance | Leadership |
Michael Holmes | Chief Scientific Officer | Leadership |
Anne-Virginie Eggimann | Chief Regulatory Officer | Leadership |
Hari Pujar | COO | Leadership |
Jacob Rubens | Co-Founder & Chief Innovation Officer | Leadership |
Howard Liang | President & CFO | Leadership |
Keith Jarvis | Executive Director, Oligonucleotide Chemistry/cmc | Leadership |
Benjamin Hall | Associate Director | Leadership |
Becky Lillie | Chief Human Resources Officer | Leadership |
Narin Ahmed | Vice President, Regulatory Science | Leadership |
Tatum A | Sr. Director, PPAM (portfolio, Program, And Alliance Management) | Leadership |
Ben Hoogheem | Senior Director, Head Of Talent Management | Leadership |
Lorenzo Tozzi | Associate Director | Leadership |
Tugba Isiker | Director Of Financial Systems | Leadership |
Megan Stellakis | Head Of HRIS | Leadership |
Lori Jackson Reed | Director Of Benefits | Leadership |
68 more people are available in the full profile.
Complete people profiles for Tessera Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Tessera Therapeutics
3 dated milestones of Tessera Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Tessera Therapeutics is founded.
- Funding First funding round of $80.0M.
- Funding Latest funding round, Series C, of $300.0M.
Competitors of Tessera Therapeutics
Tessera Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Beam Therapeutics, eGenesis and Korro Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beamtx.com | 2017 | Cambridge, United States | $222M | 340 | Developer of gene therapy using CRISPR base editing to treat diseases | |
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. |
Detailed competitors of Tessera Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Tessera Therapeutics
The website of Tessera Therapeutics (tesseratherapeutics.com) receives about 10.9K visits a month and ranks #2,061,006 among all websites worldwide, #2,809 in Biotechnology and Pharmaceuticals.
- Monthly visits10.9K
▲ 19.3% vs previous month
- Unique visitors3.9K
per month
- Global rank#2,061,006
among all websites
- Category rank#2,809
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit3.0
- Average visit1 min 03 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Tessera Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| flagshippioneering.com | 100% | 73.9K | #540,577 | View details | |
| magnetbio.com | 28% | 2K | #8,816,773 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Tessera Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tessera Therapeutics
Complete news archive for Tessera Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tessera Therapeutics
Tessera Therapeutics was founded in 2017.
Tessera Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Michael Severino is the CEO of Tessera Therapeutics, as recorded in our data.
Tessera Therapeutics is a funded company, having raised a total of $610M across 3 funding rounds to date. The company's 1st funding round was a Series B of $80M, raised on Dec 2017.
Tessera Therapeutics has 149 employees.
Tessera Therapeutics was founded in 2017 in Cambridge, United States, within the biotechnology sector. Genome engineering solutions are developed to address diseases at their genetic source. RNA-based gene writing is utilized to modify base pairs, perform small insertions or deletions, and integrate full genes into the genome. Operations center on advancing therapeutic applications for various conditions.
Tessera Therapeutics's top competitors include eGenesis, Korro Bio and Beam Therapeutics.
Tessera Therapeutics has 17 investors. Key investors include T. Rowe Price, Flagship Pioneering, Temasek, SoftBank Vision Fund, and Abu Dhabi Investment Authority.
Tessera Therapeutics operates through Tessera Therapeutics, Inc.